Featured Subject Matter Expert presentations
We will present on a number of topics that span a broad range of enabling technologies. Please see some of our featured presentations below.
APIs and Toxins/Linkers for Antibody Drug Conjugates: A Vision on Highly Potent Development, Scale-up and Manufacturing
Drug product development based on potent compounds can be quite challenging. Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost. This also applies when the potent compound is used as toxin/linker for application in ADCs. In this presentation, we will elaborate on best practices and requirements that facilitate accelerated timelines to clinic & market:
When: Wednesday 18th March, 11:00 am - 11:30 am
Technology Selection Methodologies for Poorly Soluble Molecules
A large portion of orally administered small molecules have poor absorption due to low aqueous solubility or dissolution rate. Strategies for improving oral bioavailability are becoming more widely studies and utilized in an effort to increase the oral exposure of such molecules. Selecting the optimal technology for maximizing performance, maintaining physical and chemical stability, and achieving the target product profile in vivo requires that key parameters be tailored to the specific drug and balanced relative to additional factors such as manufacturability and cost. In this presentation, we will share with you two structural motifs—"brick-dust" and "greaseball"—that span the typical compound property space for molecules with poor oral bioavailability as well as demonstrate our strategies for improving absorption of such drugs.
|When: Wednesday 18th March, 11:45 am - 12:15 pm
Venue: Seminar 1-C, West Hall 2
Speaker: Aaron Stewart, Associate Principal Scientist, Lonza Small Molecules
Enabling Cell & Gene Therapies Commercialization Through Process Development and Manufacturing Industrialization
What are the main manufacturing challenges and early development phase considerations in the field of cell and gene therapy from the CDMO perspective? Specific focus points of the presentation will include scalability, productivity, cell culture format (2D versus 3D), automation, and process analytics. Our speaker will introduce a risk assessment-based approach towards the development of cell and gene therapy processes and include best-practices in the development of cell and gene therapy products through appropriate process characterization, automation, and computer-controlled bioreactors.
|When: Wednesday 18th March, 11:00 am - 11:30 am (BioPharma Seminar)
Venue: Seminar 2-H, West Hall 4
Speaker: Lisa Krallis, Global Head of Business Development,
Lonza Cell and Gene Technologies
For more information, visit https://www.cphi.com/japan/
Contact us to schedule a meeting with our team of subject matter experts at CPhI Japan 2020